<DOC>
	<DOCNO>NCT00982150</DOCNO>
	<brief_summary>This open label treatment extension phase patient ALS previously participate double blind , placebo-controlled ALS-TAL-201 study . This study make talampanel treatment available subject complete double blind placebo-controlled phase ALS-TAL-201 study investigator patient consider patient 's interest receive talampanel 50mg three time daily ( tid ) . It also enable exploration long-term safety tolerability talampanel 50mg tid .</brief_summary>
	<brief_title>Extension Study Talampanel Amyotrophic Lateral Sclerosis ( ALS )</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<criteria>Patients must complete 52 week treatment double blind placebocontrolled phase ALSTAL201 . Women must postmenopausal , surgically sterile , use adequate birth control method . Patients must willing able give write informed consent prior perform openlabel study procedure . Patients ECG sign Brugada syndrome and/ complete incomplete Right Bundle Branch Block Patients use follow : Chronic use lithium carbonate Chronic use mecasermin ( rhIGF1 ) Chronic use minocycline Chronic use 600mg/day coenzyme Q10 Chronic use market drug , use clearly indicate underlying medical condition ALS ( symptomatic drug ALS supplement allow ) Patients participate investigational drug study use investigational drug Patients take drug may interact Talampanel Females pregnant nursing . Females childbearing potential practice medically acceptable method contraception . Any condition patient investigator feel may interfere participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Talampanel</keyword>
	<keyword>Open-Label Study</keyword>
	<keyword>Amyotrophic Lateral Sclerosis</keyword>
</DOC>